( l series has beenachieved by CeNeS sci...)Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme,Health

l series has been achieved by CeNeS scientists, and a number of discrete chemical series without the nitrocatechol group have been identified. The COMT inhibitor programme was carefully chosen by CeNeS in line with our strategy to have a low-risk profile and to address a clear commercial opportunity. A number of potent compounds are now being evaluated in the lead optimisation process, prior to selection of a development candidate.

About Parkinson's disease Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease. It affects approximately 2 per cent of the population over the age of 65, representing approximately 4 million patients worldwide. Parkinson's disease results from a loss of the neurotransmitter dopamine in the brain. Replacement therapy using L-DOPA, the precursor of dopamine, is the main treatment for Parkinson's disease. However, L-DOPA is quickly metabolised in the gut and liver allowing only a small proportion (approximately one per cent) to reach the brain. Therefore, L-DOPA is formulated with agents that inhibit the breakdown of L-DOPA by DOPA-decarboxylase, such as carbidopa and benserazide. The enzyme catechol-O-methyltransferase (COMT) also causes significant depletion of L-DOPA in the brain and periphery, limiting the efficacy of L-DOPA replacement therapy. The global market for drugs targeting Parkinson's disease was $1.7 billion in 2003 and is forecast to grow substantially over the next decade with an increased prevalence of the disease as a consequence of the ageing population. COMT inhibitors currently have more than a 10% share of the Parkinson's disease market by value and their usage is growing.

About Schizophrenia Schizophrenia is a debilitating mental illness characterized by disturbances such as hallucinations and delusions as well as a range of negative symptoms, including cognitive disturbances. Cognitive disturbances often prevent schizophrenia patients from readjusting to soci
'"/>

Page: 1 2 3 4
Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
3. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
4. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
5. Major Manufacturer of Unapproved and Adulterated Drugs
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
8. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
9. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
10. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
11. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span